Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.